J.P. Morgan Flags Large-Cap Biotech Turning Profitable as Pipelines Mature
J.P. Morgan has resumed coverage of 14 large-cap biotechnology companies, arguing the sector is shifting toward an inflection point where clinical successes are translating into profitable, diversified commercial franchises. The bank raised outlooks on multiple firms, assigning Overweight ratings to a set of companies while holding Neutral or initi…